Axsome Therapeutics (AXSM) EBITDA Margin (2022 - 2026)
Axsome Therapeutics (AXSM) posted EBITDA Margin of 33.14% for Q1 2026, down 140.93% sequentially from 13.75% in Q4 2025, and up 1378.0% YoY from 2.24% in Q1 2025.
Powered by 
Analysis
Axsome Therapeutics (AXSM) EBITDA Margin (2022 - 2026) Analysis & Trends
Axsome Therapeutics has reported EBITDA Margin for 5 years, with the latest figure at 33.14% in Q1 2026.
- Quarterly EBITDA Margin rose 1378.0% year-over-year to 33.14% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24.45% (up 6166.0% YoY) and the FY2025 annual result came in at 26.12%, up 4662.0% from the prior year.
- EBITDA Margin fell to 33.14% in Q1 2026 per AXSM's latest filing, from 13.75% in the prior quarter.
- Over five years, EBITDA Margin peaked at 6.74% in Q1 2023 and troughed at 14523.4% in Q4 2024.
- A 5-year average of 1015.03% and a median of 89.62% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin tumbled 1438601 bps in 2024, then surged 1450965 bps in 2025.
- Over 5 years, EBITDA Margin stood at 245.86% in 2022, then soared by 44 bps to 137.39% in 2023, then tumbled by 10471 bps to 14523.4% in 2024, then jumped by 100 bps to 13.75% in 2025, then sank by 141 bps to 33.14% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 33.14%, 13.75%, and 26.97% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Axsome Therapeutics | 10.75 Bn | 10.43 Bn | 204.81 Mn | -22.73% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.73% |
| Mar 31, 2026 | -33.14% |
| Dec 31, 2025 | -13.75% |
| Sep 30, 2025 | -26.97% |
| Jun 30, 2025 | -24.47% |
| Mar 31, 2025 | -46.91% |
| Dec 31, 2024 | -14,523.40% |
| Sep 30, 2024 | -59.78% |
| Jun 30, 2024 | -89.54% |
| Mar 31, 2024 | -89.70% |
| Dec 31, 2023 | -137.39% |
| Sep 30, 2023 | -107.49% |
| Jun 30, 2023 | -139.31% |
| Mar 31, 2023 | -6.74% |
| Dec 31, 2022 | -245.86% |
| Sep 30, 2022 | -251.76% |
| Jun 30, 2022 | -444.23% |